Acadia Pharmaceuticals
ACAD
155 hedge funds and large institutions have $2.08B invested in Acadia Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 48 increasing their positions, 54 reducing their positions, and 21 closing their positions.
1,549% more call options, than puts
Call options by funds: $360M | Put options by funds: $21.9M
62% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 21
38% more funds holding in top 10
Funds holding in top 10: 8 → 11 (+3)
9% more funds holding
Funds holding: 142 → 155 (+13)
5% less capital invested
Capital invested by funds: $2.18B → $2.08B (-$102M)
11% less repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 54
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$62.1M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$22M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
+$21.5M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$17.2M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
-$23.9M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$20.4M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$16.9M |
| 4 |
PA
Perceptive Advisors
New York
|
-$16.8M |
| 5 |
Alkeon Capital Management
New York
|
-$16.5M |
ACAD Hedge Fund Activity: Q4 2013 in Review
155 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q4 2013, worth a combined $2.08B — down 4.7% from $2.18B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new ACAD positions and 21 closed out — a net gain of 13 holders — while 48 added to existing stakes and 54 trimmed.
The largest buyer was Viking Global Investors, opening a new position worth an estimated $62.1M. The largest seller was Turner Investments, cutting an estimated $23.9M.
- 155 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q4 2013, up from 142 in Q3 2013.
- Funds reported $2.08B of Acadia Pharmaceuticals stock for Q4 2013, down 4.7% quarter-over-quarter.
- 34 funds opened new Acadia Pharmaceuticals positions in Q4 2013 and 21 closed out, a net change of +13 holders.
- The largest Acadia Pharmaceuticals buyer in Q4 2013 was Viking Global Investors, an estimated $62.1M added.
- The largest Acadia Pharmaceuticals seller in Q4 2013 was Turner Investments, an estimated $23.9M sold.
Based on aggregated 13F filings for Q4 2013.